Oncology Pharma Ltd. is a Switzerland-based biopharmaceutical company dedicated to acquiring, developing and commercializing innovative therapies for the treatment of cancer. Since its founding in 2009, the company has focused on building a diversified portfolio of oncology products through in-licensing agreements, strategic acquisitions and internal research programs. Oncology Pharma’s mission is to address high-unmet medical needs across a range of tumor types by advancing both small-molecule agents and biologics from early development through to regulatory approval.
The company’s portfolio encompasses marketed oncology treatments in select Eastern European and Central Asian markets, as well as a pipeline of novel candidates targeting colorectal, pancreatic and hepatocellular carcinomas. Oncology Pharma collaborates with academic institutions and contract research organizations in Europe and North America to drive clinical trials, biomarkers research and product registration efforts. Key development programs include a first-in-class receptor tyrosine kinase inhibitor in Phase II studies and an immuno-oncology vaccine approaching proof-of-concept trials.
Headquartered in Zug, Switzerland, Oncology Pharma maintains regional offices and distribution partnerships across Central Europe and the Commonwealth of Independent States, enabling direct access to physician networks and hospital channels. The company’s commercial infrastructure supports both prescription product sales and the introduction of new therapy options in specialized oncology centers. In parallel, corporate development teams continue to evaluate additional licensing opportunities in Asia and Latin America to further expand the company’s global footprint.
Under the leadership of Chief Executive Officer Dr. Martina Keller, Oncology Pharma’s management team brings extensive experience in pharmaceutical R&D, regulatory affairs and commercial strategy. Dr. Keller is supported by Chief Scientific Officer Dr. Lukas Meier and Chief Financial Officer Sabine Vogel, each of whom has played a pivotal role in securing financing, fostering strategic partnerships and executing on the company’s growth objectives. Together, the leadership team is committed to delivering new treatment options that improve outcomes for patients facing cancer worldwide.
AI Generated. May Contain Errors.
